• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Evolent Health Inc

    4/25/25 4:08:32 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email
    DEFA14A 1 d898137ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

    EVOLENT HEALTH, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


    LOGO

    Your Vote Counts! EVOLENT HEALTH, INC. 2025 Annual Meeting Vote by June 04, 2025 11:59 PM ET Hextone, Inc. P.O. Box 91421 Farmingdale, NY 11735 148,294 322,224 OF 2 Ricky Campana P.O. Box 123456 Suite 500 30# 51 Mercedes Way Edgewood, NY 11717 FLASHID-JOB# You invested in EVOLENT HEALTH, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 05, 2025. Get informed before you vote View the Annual Report, Notice & Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # XXXX XXXX XXXX XXXX Smartphone users Vote in Person at the Meeting* Point your camera here and June 05, 2025 vote without entering a 10:00 AM EDT control number Virtually at https://web.lumiconnect.com/209916247 password: evolent2025 *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com Control # XXXX XXXX XXXX XXXX THIS IS NOT A VOTABLE BALLOT EVOLENT HEALTH, INC. This is an overview of the proposals being presented at the 2025 Annual Meeting Vote by June 04, 2025 upcoming shareholder meeting. Please follow the instructions on 11:59 PM ET the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of Directors Nominees: 1A Toyin Ajayi, MD For 1B Craig Barbarosh For 1C Seth Blackley For 1D Russell Glass For 1E Peter Grua For 1F Shawn Guertin For 1G Richard Jelinek For 1H Kim Keck For 1I Cheryl Scott For 1J Brendan Springstubb For 2. Proposal to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm For for the fiscal year ending December 31, 2025. 3. Proposal to approve the compensation of our named executive officers for 2024 on an advisory basis. For 4. Proposal to approve an amendment to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive For Compensation Plan. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date. 1.00000 322,224 FLASHID-JOB# 148,294

    Get the next $EVH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    3/1/2024$45.00Outperform
    Oppenheimer
    1/3/2024$39.00Overweight
    Barclays
    More analyst ratings

    $EVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:20:54 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:18:12 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:16:20 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services
    • Define Ventures Appoints Carolyn Magill as Venture Partner

      The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

      3/11/25 5:30:00 AM ET
      $EVH
      $HIMS
      $LVGO
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care
    • Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

      Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chief Medical Officer at Blue Cross North Carolina, Deputy Associate Director of Policy and Strategy at the Centers for Disease Control and Prevention, and Senior Advisor at the Centers for Me

      12/18/24 4:10:00 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    Financials

    Live finance-specific insights

    See more
    • Evolent Announces First Quarter 2025 Results

      WASHINGTON, May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five

      5/8/25 4:10:00 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025

      Company to Participate in Upcoming Conferences WASHINGTON, April 10, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolen

      4/10/25 5:00:00 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent Announces Fourth Quarter and Full Year 2024 Results

      Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively.Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively.Adjusted EBITDA of $22.6 million for the three months ended December 31, 2024 and $160.5 million for the year ended December 31, 2024, resulting in an Adjusted EBITDA margin of 3.5% and 6.3%, respectively.Signed contract amendments in all three Performance Suit

      2/20/25 4:10:00 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $EVH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Director Holder Diane bought $25,518 worth of shares (2,735 units at $9.33), increasing direct ownership by 4% to 70,584 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:20:54 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • PRESIDENT Mccarthy Daniel Joseph bought $99,470 worth of shares (11,040 units at $9.01), increasing direct ownership by 3% to 389,004 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:18:12 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Director Jelinek Richard M bought $273,750 worth of shares (30,000 units at $9.12) (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      3/10/25 8:16:20 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

      SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

      11/12/24 9:55:15 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

      SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

      8/7/24 7:47:40 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Evolent Health Inc

      SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)

      7/10/24 10:10:34 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent Announces First Quarter 2025 Results

      WASHINGTON, May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. We continue to see a very strong selling environment and we achieved significant organic growth with five

      5/8/25 4:10:00 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors

      Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability.Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts.WASHINGTON, April 22, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that a new director nominee will stand for election to the Board of Directors at the annual meeting of stockholders scheduled to be held on June 5, 2025. The Board has recommended Mr. Shawn Guertin for election. Mr. Guertin is an insurance and health care executive with nearly 40 years of actuarial, fina

      4/22/25 6:30:00 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent program achieves 20% reduction in use of low-value oncology regimens

      Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain. Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens. One low-value regimen costs about 70 times more than a clinically equivalent alternative.WASHINGTON, April 15, 2025 /PRNewswire/ -- When treating patients with cancer, oncologists typically can choose from multiple FDA-approved regimens, or combinations of drugs. While tools such as Evolent's clinical pathways can help them find high-value options, providers have not had similar resources to flag regimens on the opposite side of the spec

      4/15/25 9:00:00 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Evolent Health with a new price target

      Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00

      1/10/25 7:49:47 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • BTIG Research reiterated coverage on Evolent Health with a new price target

      BTIG Research reiterated coverage of Evolent Health with a rating of Buy and set a new price target of $29.00 from $36.00 previously

      12/3/24 7:52:53 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Evolent Health downgraded by Stephens with a new price target

      Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously

      11/8/24 7:50:07 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary

    $EVH
    SEC Filings

    See more
    • Evolent Health Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Evolent Health, Inc. (0001628908) (Filer)

      5/8/25 4:12:58 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • SEC Form DEFA14A filed by Evolent Health Inc

      DEFA14A - Evolent Health, Inc. (0001628908) (Filer)

      4/25/25 4:08:32 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • SEC Form DEF 14A filed by Evolent Health Inc

      DEF 14A - Evolent Health, Inc. (0001628908) (Filer)

      4/25/25 4:07:12 PM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary